TMCnet News
Riverain Technologies™ Expands Partnerships for Automated, Efficient End-to-End Lung Cancer Screening CapabilitiesRiverain Technologies™, a leader in artificial intelligence (AI) for early, efficient detection of lung nodules, today announced the growth of its relationships across the lung imaging ecosystem at the 107th Annual Radiological Society of North America (RSNA) meeting, November 28-December 2, 2021 (South Hall #4129). Riverain's partnerships with OEMs, AI vendors, PACS providers, and reporting and patient management companies have grown in depth and breadth, providing customers with a more seamless enterprise-wide access to earlier, more efficient detection of lung abnormalities. "Riverain was proud to introduce the first FDA approved chest algorithm almost 10 years ago and we are dedicated to continuously enhance our technology to improve clinical accuracy and efficiency," said Steve Worrell, CEO. "At the same time, by expanding partnerships with key players across the ecosystem, we continue to deliver on an important promise to our users: your acquisition, your workflow, your peace-of-mind." Riverain will highlight its many strategic partnerships complementing the ClearRead suite of applications, providing enhanced end-to-end lung imaging and cancer screening capabilities:
About Riverain Technologies Riverain is dedicated to the early, efficient detection of lung disease. Riverain believes the opportunities for machine learning and software solutions in healthcare are at an unprecedented level. Never before has the opportunity to 'do more with less' been so great. We believe tools incorporating increasing degrees of intelligence will facilitate decision making, leading to improved patient outcomes. For more information, please visit www.riveraintech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005463/en/ |